Staple peptides represent a genuinely new frontier in medicine, said Professor Gregory Verdine, Harvard University, USA, when speaking this week at the 241st National Meeting of the American Chemical Society.
Prof. Verdine went on to say that these staple peptides are able to address targets previously considered “undruggable” by conventional therapeutics, such as small-molecule agents. In one advance, a staple peptide was able to target beta-catenin, an aberrant protein implicated in the progression of colon cancer and other types of cancer such as skin, brain and ovarian.
Studies are ongoing to establish the potential of these staple peptides as novel therapeutics.
- Watch video on his talk
Potential new medicines show promise for treating colon cancer, asthma
Other articles related to the ACS meeting
- Removal of Strontium From Nuclear Waste
Removal of strontium from nuclear waste streams by desmid green algae - Hollywood Chemistry
And the Winner for the Most Accurate Science in a Movie or TV series goes to … - Kevlar-like Plastic from Pineapples and Bananas
Nano-cellulose fibers from plants may lead to stronger, lighter, and more sustainable materials to replace automotive plastics - Charles Lathrop Parson Award
Michael E. Strem, president of high purity chemicals maker Strem Chemicals, receives the ACS award for outstanding public service - Priestley Medal Awarded
Ahmed H. Zewail, California Institute of Technology, USA, awarded ACS’s highest honor Priestley Medal Awarded - Dendrimersomes: A New Mode of Drug Delivery?
Amphiphilic branched nanostructures self-assemble in water to form packets capable of mimicking biological membranes
